QuidelOrtho Corporation, a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary revenue results for the first quarter ended April 2, 2023.

On April 6, Sinocare released its annual report for 2022.

Righton Gene announced on April 9 that in 2022, the company achieved operating revenue of CNY 424 million, up 45.83% year-on-year; attributable net profit of CNY 40,473,600, down 14.49% year-on-year; basic earnings per share of CNY 0.73.

DiaSorin said on Monday that its full-year 2022 revenues grew 10 percent year over year on "solid performance" across all its businesses.

Point-of-care diagnostics firm LumiraDx on Tuesday reported a 65 percent decrease in its fourth quarter revenues.